LATEST NEWS
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Rare cancer patients still have limited access to personalised care in Europe
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Can AI chatbots effectively support patients with cancer during treatments?
Early findings suggest potential benefits in symptom monitoring, but highlight usability challenges and added burden on clinical workflows
OTHER NEWS
Meta-analysis shows non-inferiority of later versus earlier immunotherapy administration in lung cancer
Chrono-immunotherapy may influence treatment outcomes, especially during the early phase of treatment, but its overall clinical impact remains to be clearly defined
CTLA-4 targeting leads to improved overall survival in NSCLC progressing on immunotherapy
Early phase III trial results signal a much-needed chemotherapy-free advance with gotistobart in a setting where therapeutic choices are limited
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
FROM GUEST EDITORS
A driving force to accelerate drug development
Fostering academic clinical research is one of the ESMO’s priorities, and artificial intelligence may be a major driver
Why clinical practice guidelines matter even more in rare cancers
A recent EURACAN survey highlights a high uptake of recommendations from medical oncologists, potentially leading to improved patients’ survival
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
OPINIONS
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
Can the benefits of lung cancer screening be extended to never-smokers?
Joachim G. Aerts
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Umberto Malapelle
OPINIONS
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
Overcoming resistance to immunotherapy in NSCLC?
Alessandra Curioni Fontecedro
Can the benefits of lung cancer screening be extended to never-smokers?
Joachim G. Aerts
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Umberto Malapelle